207 related articles for article (PubMed ID: 9850439)
1. Clinical advantages of lipophilic dihydropyridines.
Mancia G; Omboni S; Zanchetti A
Blood Press Suppl; 1998; 2():23-6. PubMed ID: 9850439
[TBL] [Abstract][Full Text] [Related]
2. Lercanidipine in the treatment of hypertension.
Beckey C; Lundy A; Lutfi N
Ann Pharmacother; 2007 Mar; 41(3):465-73. PubMed ID: 17341540
[TBL] [Abstract][Full Text] [Related]
3. Lercanidipine in hypertension.
Borghi C
Vasc Health Risk Manag; 2005; 1(3):173-82. PubMed ID: 17319103
[TBL] [Abstract][Full Text] [Related]
4. [Lercanidipine, a third generation calcium antagonist. Which advantages?].
Meier P; Burnier M
Rev Med Suisse; 2006 Sep; 2(78):2047-50, 2052-3. PubMed ID: 17019840
[TBL] [Abstract][Full Text] [Related]
5. Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?
Burnier M; Pruijm M; Wuerzner G
Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):981-7. PubMed ID: 19619074
[TBL] [Abstract][Full Text] [Related]
6. Hypertension, possible vascular protection and lercanidipine.
Ram CV
Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):783-8. PubMed ID: 17173495
[TBL] [Abstract][Full Text] [Related]
7. Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study.
Barrios V; Escobar C; de la Figuera M; Llisterri JL; Honorato J; Segura J; Calderón A
Cardiovasc Ther; 2008; 26(1):2-9. PubMed ID: 18466416
[TBL] [Abstract][Full Text] [Related]
8. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina).
Dalla Vestra M; Pozza G; Mosca A; Grazioli V; Lapolla A; Fioretto P; Crepaldi G
Diabetes Nutr Metab; 2004 Oct; 17(5):259-66. PubMed ID: 16295047
[TBL] [Abstract][Full Text] [Related]
9. Antihypertensive effects of lercanidipine in experimental hypertensive rats and dogs.
Sironi G; Montagna E; Greto L; Bianchi G; Leonardi A; Testa R
Arzneimittelforschung; 1996 Feb; 46(2):145-52. PubMed ID: 8720303
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of lercanidipine in the general practice setting].
Robles NR; Canelada JA; Iglesias M; Angulo E; López Acedo A; Díaz Olea E; Cidoncha F; Guerras M; Fuentes J; Garrido J; Lapie J; Peña J; Aguilar A; Hidalgo P
An Med Interna; 2003 Jun; 20(6):282-6. PubMed ID: 12848597
[TBL] [Abstract][Full Text] [Related]
11. [Drug information about lercanidipine. A new dihydropyridine calcium antagonist for the treatment of arterial hypertension].
Christensen KL
Ugeskr Laeger; 2005 Jan; 167(2):153-5. PubMed ID: 15697124
[No Abstract] [Full Text] [Related]
12. Renal effects of calcium antagonists with special reference to manidipine hydrochloride.
Rodicio JL
Blood Press Suppl; 1996; 5():10-5. PubMed ID: 8973787
[TBL] [Abstract][Full Text] [Related]
13. Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers.
Makarounas-Kirchmann K; Glover-Koudounas S; Ferrari P
Clin Ther; 2009 Aug; 31(8):1652-63. PubMed ID: 19808126
[TBL] [Abstract][Full Text] [Related]
14. The role of fixed-dose combinations in the management of hypertension: focus on lercanidipine-enalapril.
Chatzikyrkou C; Haller H; Menne J
Expert Opin Pharmacother; 2009 Aug; 10(11):1833-40. PubMed ID: 19527194
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Palmieri V; Devereux RB
Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
[TBL] [Abstract][Full Text] [Related]
16. Lercanidipine vs lacidipine in isolated systolic hypertension.
Millar-Craig M; Shaffu B; Greenough A; Mitchell L; McDonald C
J Hum Hypertens; 2003 Nov; 17(11):799-806. PubMed ID: 14578921
[TBL] [Abstract][Full Text] [Related]
17. Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine.
Pruijm MT; Maillard MP; Burnier M
Vasc Health Risk Manag; 2008; 4(6):1159-66. PubMed ID: 19337529
[TBL] [Abstract][Full Text] [Related]
18. The pharmacological properties of lipophilic calcium antagonists.
van Zwieten PA
Blood Press Suppl; 1998; 2():5-9. PubMed ID: 9850436
[TBL] [Abstract][Full Text] [Related]
19. [The effect of calcium channel blocker lercanidipine on lowgrade inflammation parameters in essential hypertension patients].
Shurtz-Swirski R; Farah R; Sela S; Shapiro G; Klempef R; Snitkovski T; Kristal B
Harefuah; 2006 Dec; 145(12):895-9, 942. PubMed ID: 17220028
[TBL] [Abstract][Full Text] [Related]
20. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
Oparil S; Bakir SE
Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
